Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer withdraws EU application for OTC Viagra

This article was originally published in Scrip

Executive Summary

Pfizerhas withdrawn its centralised European application to switch the 50mg tablet form of Viagra (sildenafil) to non-prescription status after concerns were raised about the supply of the product without a prescription in the EU.

You may also be interested in...



EU Calls For COVID-19 Diagnostic Research Projects

As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats. 

EU Call For Coronavirus Projects Sparks Big Pharma Interest

Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.

EU Funding For COVID-19 Drug & Diagnostic Research

Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.

Related Companies

UsernamePublicRestriction

Register

SC031895

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel